drugset / Trial / NCT04203056
Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode
RandomizedParallel-groupOpen-labelTreatment
Summary
This 12-month study will evaluate the efficacy of aripiprazole lauroxil compared to oral aripiprazole in preventing the re-emergence of psychotic symptoms in patients with a recent onset of schizophrenia.
Timeline
- Start
- 2019-12-16
- Primary completion
- 2022-10-01
- Completion
- 2022-10-01
Outcome
Outcome not reported
Stopped (Business): “Withdraw of financial support by industry collaborator”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aripiprazole | Other / unclassified | — | Oral |
| Subject | Aripiprazole Lauroxil | Small molecule | — | Intramuscular |
| Background | AL-NCD | Unknown | 675 mg | Intramuscular |